Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone follow Motif Bio? Any opinion on their new antibiotic which is coming up for approval on the 13th this month.
Barry
Voclosporin
Though Voclosporin showed some impressive efficacy results in their phase 11 trial, the SAE'S were another matter with 13 deaths reported. Does anyone here have an explanation for the deaths that does not relate to the toxic nature of the drug?
Thanks in advance
Barry
I have been doing some DD to evaluate this security as a place to park some of my Aria gains. Though it certainly appears that Voclosporin's phase 11 showed impressive efficacy results, I am concerned about the 13 deaths reported. Does anyone here have any information as to a possible explanation for the deaths that does not reflect on the toxicity of the drug?
Thanks in advance for any information you can share on this issue.
Barry
Thanks, I will continue my DD
Barry
Vidpok
My understanding is that their clinical trial is testing the drug in combination with the Standard of Care drug "Mycophenolate Mofetil" . When I researched this later drug, it appears that in 3 years or so, the market for "Mofetil" is expected to reach $125 Million, Have you read anywhere that Auph believes Voclosporin can address a bigger market (indication)?
Barry
My educated guess is that he was SHORT, what else can explain the vicious way in which he went after the BOD with the Sec
Barry
oops I meant and he was probably NOT a long.
Perhaps we didn't hear from him because he was really on the other side and a long.
Barry
Hey Sekander,
I am a tax atty and if you want an answer to that question, please email me at Barrytaxes815@aol.com
Barry
Just came off an aria victory and looking at arry to invest some of the aria funds, Can someone please give me a realistic time frame for the approval of their first drug.
Thanks in advance and hoping to join the longs on the board.
Barry
Short Hedge? or Betting on a Spike?
Someone bought 1,714 (December 16th 2016) 14 calls today, and it appears that they paid 40 cents a call.
Do you think it was a short hedging their bet? or someone betting on a spike? Hmmmmm
Barry
Wish it were me. I bought the Jan 20 2016 strike price 13
B
The strike price was 14
Someone is betting on the conference
Look at the options, 2,111 Dec 2nd 2016 Calls bought today.
Hmmmm
Barry
What price?
Does anyone know how much Ariad is charging for the compassionate use of Brigatinib?
Barry
Regarding Brigatinib, the FDA will announce whether, or not, they have granted "early review " of our NDA, within the next 14 days. I say this because according to FDA rules, they have 60 days to act upon the request, which I believe was submitted on August 30th.
Barry
This attempt to litigate is confusing.
It does not appear that they are attempting to certify a class action on behalf of the patients and Insurance companies, claiming that they paid too much for the drug. Based on the scant information in the news article, they are attempting to certify a class action on behalf of Ariad investors. As the price of the drug increased, rather then decreased, Ariad investors did not sustain stock losses, but stock gains, so where are the damages?
I hope someone can explain why this is being considered
Has anyone heard any news about the abstracts and posters that Ariad reported on this weekend?
Barry
I wonder if Onduo, Google & Sanofi's new diabetes bio startup, who is locating in Kendall Square, will be Ariad's new sub tenant.
The deal was made with Otsuka and announced on 12/23/14, Ariad received an upfront payment of 77.5 Million and will receive an additional milestone (announcement is silent as to the amount) when Ponatinib is approved for patients with resistant or intolerant Philadelphie-positive Leukemia. Trials for any other indications will be paid by Otsuka and if Ponatinib is approved for any other indications, Ariad to receive additional milestone payment for each such approval. Ariad also gets 'substantial" share of net sales of Ponatinib.
Barry
Does Ariad still own AP20187 ?, or did it sell it to Bellicum or another Bio?
Barry
JESS
With all due respect, the implication of your post is, to say the least, very misleading and not based upon what is happening in the "real world"
These 105-b plans are almost always put in place many months before the events that led to the salling and profiting that you stated. Are you implying that the insiders who sold, had some sort of crystal ball, which tipped them off as to events that were about to occur many months in the future?
I strongly suspect, that most of the sales and profits that you refer to were simply made in due coarse and purruant to the pre-determined sale dates decided on many many months before the events that gave rise to the profits on the exercise of the planned sales. More likley, the insiders that made these sales "got lucky" and it was pure coincidence that these events happened just prior to the planned sale. I am sure that on the pre-determined date that a 105-b plan sale was scheduled for, if the price of the stock was below the price that the insider choose to sell at, he, or she would have just skipped the sale (which I believe that they have a right to do). So if I am correct, that is why you seldom hear about planned 105-sales occurring when the insider losses a bundle on the sale.
Regards,
Barry
Likewise
Though I am probably not the only one, but as the reident tax attorney on this board, and for those concerned with the relatively small (position wise) security sales of Ariad shares by several insiders. allow me to remind you folks, that in less than two (2) weeks, we, who are required to, will have to come up with the money to pay ESTIMASTED TAXES.
Barry
I say this because of this statement by Timmy
"and now we are closing in on the filing of a NDA"
That does not sound like something that might happen in six (6) months or a year from now.
Barry
I have a feeling
I have a feeling that the morning before the ASM, we will learn that Briga is fully enrolled and that will set us up for the filing of a ND application before years end.
We are, after all, in the third quarter and the way Clackson talked about the filing of the ND application, it sounds like it will happen before 2016.
Barry
Why do you say that? I can see that both the delay in the annual meeting, and a proposal to take the company private is possible and that is why the meeting is being held in a law office.
Would you care to take a guess as to why the annual meeting venue changed?
Barry
I just sent an email to Kendra asking why the meeting is so late and in the lawyer's office. My gut tells me that it can't be good news. Let's see if she responds
Barry
You may be right", but I am not sure as to what Harvey meant by this phrasing, "Iclusig, Brigatinib and threee behind that" If he was referring to the drugs you mention, perhaps he could have phrased it as " another already announced and two previoulsly discovered drugs"
Anyone care to weigh in on this discussion?
Barry
Please do, because she rarely responds to my emails.
Thanks, but Harvey certainly referred to several other drugs in his presenation today. I am especially intrigued by his stating that two (2) are for indications other than Cancer. Hmmmmm perhaps an auto immune drug? Alzheimers?
Barry
Just listened to the Goldman Sachs presentation and one of Harvey's first statements left me wondering. At the beginning of his prentation, and in response to what his legacy will be, Harvey said that he is proud of the two drugs that Ariad producd (obviously referring to Icluisig and Brigatinib) and mentioned that they will be followed by three (3) others, and of the five, three are in the oncology field (I am sure that was Iclusig, Brigatinib and 788) and the other two (2) will be for other indications.
Does anyone here have any information on the other two that Harvey was referring to? Perhaps someone has heard some reference to these other two candidates, at one of the Medical Conferences, other presentations, facebook or annual meetings?
Barry
And to show you how tight the ownership of Ariad is, just 17 institutions and mutual funds, own slightly over 60% of the company.
That certainly appears to be telling us something Hmmmmmmmm
Barry
Wow that sounds good, but in March of 2000, one of the biotechs zoomed over 9,600% in just three (3) short months. In December of 1999 it was selling for .50 a share and by March 11th 2000 (I believe that is the date) the stock zoomed to 48 5/8.
The name of this Rocket is Ariad Pharmaceuticals.
Barry
If my memory serves me right, Morgan Stanley brought them public. That is to the best of my recollection, because I represented one of the brokers who sold quite a bit of the $25,000 units of the issue to his clients, and Morgan was offering a bonus (consisting of Ariad common) to the brokers for each unit sold. Prior to the issuance of these bonus shares to my client, he left Morgan Styanley for another firm and Morgan Stanley refused to give him the bonus shares and I was able to get him a very nice settlement with them.
Barry
Re: "788"
My guess is that "788" (NM) will address the EGFR mutation, as Aria was hot on the trail of EGFR when they developed "113", but missed.
That would be a huge market.
Barry
Chugai
There is very recent evidence of a patient doing well on Chugai for several months and just developed a number of brain mets.
It may very well be that Chugai is unable to deal with brain mets, and if that is the actual case, then 113 may very well be differentiated from the drug that just was fast tracked.
Perhaps we will get some clarifying data this weekend at ESMO,
JMHO
Barry
ESMO
Does anyone have a list of the presentations and or posters, relating to Iclusig and 113, that will be presented at ESMO?
Thanks in advance,
Barry
Three Corners Hotel is also on the water, in the town of Liberia, If you see it. let me know how it looks, I have not been there in 5 years,
Barry